Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 8:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 33 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Not yet recruiting Phase 1 Interventional

Cannabis and Opioid Use Disorder, Study 2

NCT07661446
Conditions
Opioid Use Disorders, Cannabis Use
Interventions
Inhaled Cannabis, Intranasal Opioid
Drug
Lead sponsor
University of Kentucky
Other
Eligibility
18 Years to 55 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Lexington, Kentucky
Conditions
Opioid Overdose
Interventions
Enhanced Overdose Education (EOE), Standard education
Behavioral
Lead sponsor
Hartford Hospital
Other
Eligibility
21 Years to 65 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
Hartford, Connecticut
Completed Not applicable Interventional Accepts healthy volunteers

Developing a Clinical Outcome Assessment for Opioid Craving

NCT05109429
Conditions
Opioid Craving, Opioid Use Disorder, Measure Development
Interventions
Neutral Cue-induced Craving, Visual Opioid Cue-induced Craving, Visual and Tactile Opioid Cue-induced Craving
Behavioral
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Opioid Overdose
Interventions
Nalmefene HCl injection, Naloxone HCl intranasal
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Harm Reduction, Opioid-use Disorder, Naloxone
Interventions
Nasal Spray Naloxone, Intramuscular Naloxone, Improvised Nasal Atomizer
Device
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Syracuse, New York
Completed Early Phase 1 Interventional Accepts healthy volunteers

Methadone Oxytocin Option

NCT01728909
Conditions
Substance Abuse, Opioid Dependence, Methadone Treatment
Interventions
Oxytocin, Saline Nasal Spray
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Male only
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
San Francisco, California
Conditions
Healthy Subjects, Opioid Antagonist, Pharmacokinetics
Interventions
Four naloxone nasal spray doses (1 every 2.5 min), Four naloxone nasal spray doses (2 every 2.5 min), Two naloxone nasal spray doses (1 every 2.5 min)
Drug
Lead sponsor
Food and Drug Administration (FDA)
Federal
Eligibility
18 Years to 55 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
West Bend, Wisconsin
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacodynamic Evaluation of Intranasal Nalmefene

NCT04828005
Conditions
Pharmacodynamic
Interventions
Nalmefene hydrochloride, Naloxone hydrochloride
Drug
Lead sponsor
Opiant Pharmaceuticals Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Salt Lake City, Utah
Completed Phase 1Phase 2 Interventional Results available

Oxytocin Treatment of Opioid Dependence

NCT02548728
Conditions
Opioid Dependence, Opioid Withdrawal
Interventions
Intranasal Oxytocin Spray, Placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
21 Years to 45 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Opioid Use Disorder, Cocaine Use Disorder
Interventions
Oxytocin, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
San Francisco, California
Conditions
Recreational Drug Use
Interventions
PF614, Oxycodone, Placebo
Drug · Other
Lead sponsor
Ensysce Biosciences
Industry
Eligibility
18 Years to 55 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Columbus, Ohio
Completed Phase 1 Interventional Results available

Oxytocin, Stress, Craving, Opioid Use Disorder

NCT04051619
Conditions
Opioid Use Disorder
Interventions
intranasal oxytocin, 40 IU, twice a day for 7 days
Drug
Lead sponsor
Brown University
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Providence, Rhode Island
Completed Not applicable Interventional Accepts healthy volunteers Results available

Aprepitant Effects on Oxycodone Response

NCT00999544
Conditions
Narcotic Abuse
Interventions
Aprepitant 0mg, Aprepitant 40mg, Aprepitant 200mg, Oxycodone 0mg, p.o., Oxycodone 20mg, p.o., Oxycodone 40mg, p.o., Oxycodone 0mg, IN, Oxycodone 15mg, IN, Oxycodone 30mg, IN
Drug
Lead sponsor
Sharon Walsh
Other
Eligibility
18 Years to 55 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Lexington, Kentucky
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Abuse Potential of Intranasal Cebranopadol

NCT06453265
Conditions
Abuse, Drug
Interventions
Cebranopadol- 600 ug, Cebranopadol- 800ug, Cebranopadol- 1000ug, Treatment A:, Treatment B, Treatment C, Qualification
Drug
Lead sponsor
Tris Pharma, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Columbus, Ohio
Recruiting Phase 2Phase 3 Interventional Accepts healthy volunteers

Naltrexone for Overdose Prevention

NCT06633900
Conditions
Overdose Accidental
Interventions
IM naltrexone, Usual Care
Drug · Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
San Francisco, California
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Sprix for Postoperative Pain Control Following Gynecologic Surgery

NCT04444830
Conditions
Post Operative Pain Control, Narcotic Use, Pelvic Organ Prolapse, Urinary Incontinence , Stress, Surgery
Interventions
Sprix
Drug
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Louisville, Kentucky
Conditions
Opioid Overdose
Interventions
16 mg naloxone AP003, 8 mg naloxone NARCAN Nasal Spray
Combination Product
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Miami, Florida
Conditions
Aneurysmal Subarachnoid Hemorrhage (aSAH), Headache
Interventions
Lidocaine (drug), Tx 360
Drug · Device
Lead sponsor
Wright State University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Dayton, Ohio
Conditions
Opioid-Related Disorders
Interventions
Placebo taken first, Generic H/A taken first, Vycavert taken first, Generic H/A plus i taken first, Generic H/A plus p taken first
Drug
Lead sponsor
Acura Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Healthy
Interventions
MNS075
Drug
Lead sponsor
Javelin Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Austin, Texas
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Reinforcing Effects of Intranasal (IN) Buprenorphine Versus Buprenorphine/Naloxone

NCT01760473
Conditions
Heroin Dependence
Interventions
Intranasal challenge drug
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 45 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
New York, New York
Not listed Not applicable Interventional Accepts healthy volunteers

Mobile Intervention for Young Opioid Users

NCT03610672
Conditions
Opioid-Related Disorders
Interventions
OD prevention/response training, OD prevention/response training + PI mobile application
Behavioral
Lead sponsor
National Development and Research Institutes, Inc.
Other
Eligibility
18 Years to 29 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
New York, New York
Conditions
Pain, Virtual Reality, Placebo, Temporomandibular Disorder
Interventions
Active Virtual Reality, sham Virtual Reality, No Intervention, Naloxone, Saline, Natural history
Behavioral · Other · Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 88 Years
Enrollment
259 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Advanced Cancers, Pain
Interventions
Fentanyl Nasal Spray, Hydromorphone Hydrochloride, Phone Call
Drug · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Houston, Texas